SAN DIEGO, June 13, 2023 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting DFC candidate, as well as the development of its novel drug-Fc conjugates (DFCs) from Cidara's Cloudbreak® platform, at the 2nd Annual Adenosine-Pathway Targeted Cancer…
wpengineJune 13, 2023